WS
William John Sibold
President and CEODirector

William John Sibold insider trades: Madrigal Pharmaceuticals (MDGL) stock sales

President and CEO, Madrigal Pharmaceuticals Last trade Sep 11, 2026 14 Form 4 filings
$10.5M
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2024
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where William reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 11, 2026MDGL↓ Sell$6.2M
Jul 20, 2026MDGL↓ Sell$1.4M
Mar 6, 2026MDGL↓ Sell$718K
Jan 26, 2026MDGL↓ Sell$777K
Dec 4, 2025MDGL↓ Sell$1.4M
Sep 9, 2025MDGL↓ Sell$3.2M
Aug 21, 2025MDGL↓ Sell$3.0M
Jan 24, 2025MDGL↓ Sell$531K
Sep 9, 2024MDGL↓ Sell$1.6M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other MDGL insiders

Open-market trades in the last 12 months

About William John Sibold's insider trades

William John Sibold is President and CEO at Madrigal Pharmaceuticals (MDGL). Since Sep 9, 2024, William has reported no open-market purchases and 9 sales worth $18.9M on SEC Form 4. In the last 12 months: 5 sales ($10.5M).

Their filings also include grants and awards (5 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MDGL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.